Comprehensive results of ESG401, a TROP2-targeting ADC: Updated phase 1 analysis in advanced solid tumors. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not ...
Monoclonal antibodies (mAb) and antibody-drug conjugates (ADCs) are widely used biological therapeutics. A key property of these biologics is the extent and rate of internalization into different ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results